FRANKLIN, Mass.– Cohesive Technologies Inc.
(http://www.cohesivetech.com) announced that it has entered into a
collaborative agreement with Mayo Clinic to increase patient sample
throughput and improve data quality using Cohesive’s proprietary turbulent
flow chromatography (TurboFlow(R) technology) systems for clinical assays
using tandem mass spectrometry (MS/MS).
The collaboration has been established to accelerate the development of clinical assays in such areas as endrocrinology, toxicology, drug
monitoring, and neonatal screening. As part of the collaboration, the
companies will share in the development of new TurboFlow and mass
spectrometry methods in order to improve the quality and efficiency in
diagnostics for adults, children, and newborns. These methods will be based on Mayo Clinic’s goals for throughput and the potential impact to patients.
While tandem mass spectrometry is being widely adopted in clinical
diagnostics to drive down false positives and improve limits of detection,
these labs struggle with the lengthy sample preparation required and high
capital costs associated with tandem mass spectrometry. Cohesive’s systems
have been adopted because they address these sample preparation bottlenecks and also reduce capital requirements, thus making MS/MS more economically feasible for the diagnostic marketplace.
Cohesive Technologies develops, manufactures, and markets novel liquid chromatography systems and chemistries for the pharmaceutical,
biotechnology, and clinical diagnostic marketplace.